Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
March 14, 2022
Ryan Allway March 14th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today... Read more
Zollaris Laboratories Corp. Receives Health Canada authorization to investigate PSILOCYBIN (PSYCHEDELIC MUSHROOMS) for potential new therapeutics
February 16, 2022
Ryan Allway February 16th, 2022 Psychedelics, Top News Psilocybin therapy is being investigated by Zollaris for the treatment of mental health and other unmet medical needs HAWKESBURY PROVIDENCE, Ontario, Feb. 16, 2022 /PRNewswire-PRWeb/ — Zollaris Laboratories Corporation. (hereafter, “Zollaris”) receives authorization from the Health Canada, Office of Controlled Substances for analytical investigation of several... Read more
AIkido Pharma Announces Third Quarter Highlights and Corporate Update
November 11, 2021
Ryan Allway November 11th, 2021 Highlights recent investments in Electric Vehicles, Cannabis, Tele-health & Innovative Sports Businesses with near term monetization and liquidity events forthcoming NEW YORK, Nov. 11, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced its third quarter ending September 30, 2021, financial highlights... Read more
